We are a leading e-health company providing smart, reliable and user-friendly solutions to improve healthcare and patient safety. We are one of the largest suppliers in Scandinavia and a growing player in the European market, with more than 170,000 users across general and university hospitals, health centers and specialist units. We are growing continuously and now have over 700 employees in our offices in Sweden, Denmark, United Kingdom and Sri Lanka.
About Cambio
Corporate structure
Regulatory reports
Cambio receives MDR certification for EHR-system and clinical decision support
Cambio Interim Report Q2 2024
Sanolium interim report Q1 Jan-Mar 2024
Sanolium AB today released its annual report and sustainability report for 2023
Sanolium publishes bond prospectus and applies for listing of its bonds on Nasdaq Stockholm
Sanolium announces that the condition for the early redemption of its outstanding 2019/2024 bonds has been satisfied
Sanolium successfully announces results from the tender offer
Sanolium successfully issued new senior secured bonds of SEK 1,000m
Cambio Year End Report Q4 2023
Sanolium contemplates issuance of new senior secured bonds, announces a conditional tender offer for its outstanding 2019/2024 bonds and gives a conditional call notice of early redemption
Interim report Q3 2023
KGC regions extends agreement regarding support and maintenance of the electronic health record system Cambio COSMIC
Sanolium AB interim report April - June 2023
Sanolium AB interim report, January - March 2022
Sanolium interim report Q4 oct-dec 2022
Sanolium AB interim report, July – September 2022
Cambio strengthens position as market leader by acquiring FRISQ AB
Cambio and FRISQ enters into a formal exclusive process to divest FRISQ to Cambio with a target transaction date in September 2022
Sanolium AB interim report, January - March 2022
Johannes Fabó new Chief Financial Officer at Cambio
Read our press releases
Read older press releasesEarlier reports
2023
2022
2021
2020
2019
2018
Financial calendar
Interim report Q2, April-June: 2024-08-30
Interim report Q3, July-September: 2024-11-29
Annual Report 2024: 2025-02-28